INTRODUCTION
It is generally accepted that bile salts play a central role in bile formation and lipid absorption in the adult (1) (2) (3) . It is only gradually coming to be appreciated, however, that these compounds are of importance to the newborn, and may serve functional roles in the fetus. The fetal development of bile salt synthesis and metabolism has not been completely delineated. Blood, gallbladder, and intestinal bile salt concentrations have been measured in near-term fetuses, premature infants, and newborns (4) (5) (6) (7) (8) (9) (10) . The gallbladder and intestinal bile salts of fetal and neonatal rabbits have been identified and quantified (11) . Bile salt synthesis, 1042 secretion, and turnover have been measured in the near-term fetuses of large laboratory animals (12) (13) (14) (15) (16) . Pool size and synthesis rates have been determined for newborn infants using stable isotope techniques (17, 18) or by measuring fecal bile salt excretion (10, 19) . Excess quantities of bile salt precursors have been identified in the duodenal fluid or excreta of some infants with cholestatic syndromes, and this might suggest the presence of developmental defects of bile salt synthesis (20) (21) (22) .
Technical factors have precluded a more complete study of the ontogenesis of bile salt metabolism: cost and scarcity have ruled out the use of large laboratory animals, whereas the insensitivity of standard quantitative techniques for bile salt determination have made a study in small laboratory animals impossible. Recently developed radioimmunoassays (RIA)l for bile salts (23, 24) provide the necessary sensitivity for such measurements but are not specific for the taurine conjugates which are predominant in most small animals. We have now developed an RIA for taurocholate, the principle bile salt in rats. The assay is several orders of magnitude more sensitive than gas-liquid chromatography (GLC) , is highly specific for taurocholate, and is simple to perform. With this RIA, we have measured the amount and distribution of taurocholate in fetal and neonatal rats, and have examined the effect of maternal adrenocorticosteroid and phenobarbital administration on these parameters.
METHODS

RIA of taurocholate
Antigen preparation. Taurocholate and [3H]taurocholate purchased commercially (Calbiochem-Behring Corp., American Hoechst Corp., Calif. and New England Nuclear, Boston, Mass.) were shown to be 99% pure by thin-layer chromatography on silica gel G in three solvent systems. The mixed anhydride of taurocholate was prepared using established techniques (25) by adding 0.4 ml (1.5 mmol) of isobutylchloroformate to a stirred solution maintained at 8WC, which contained the following constituents: 0.82 g (1.5 mmol) 'Abbreviations used in this paper: B/Bo, ratio of counts bound at a specific dose level to those bound at zero dose; GLC, gas-liquid chromatography; RIA, radioimmunoassay(s). The effect of dexamethasone on the accumulation and distribution of taurocholate vas studied. Pregnant rats were injected subcutaneously daily with 60 gg of dexamethasone dissolved in 0.02 ml of ethvlene glycol and 0.98 ml of saline from day 9 of gestation until sacrifice at day 15 or 19 of gestation or 1 d after birth. A second short-term treatment group was injected with the same dose of dexamethasone for 3 d before sacrifice. Control animals were injected with the ethylene glycol-saline carrier only.
Comparable studies were conducted in which phenobarbital, 100 mg/kg per d, dissolved in distilled water, was injected subcutaneously into pregnant rats from gestational day 9 until sacrifice at day 16 or 19. This dose of phenobarbital induced anesthesia for 10-12 h daily. Food was withheld from control animals during this period. A second group of pregnant rats was injected with 50 mg/kg per d for 3 d before sacrifice on day 19 and compared with suitable controls.
Analytic procedures
Tissue homogenates, with 800 cpm [3H]taurocholate added for recovery determination, were extracted with chloroformmethanol by a modification of the method of Folch et al. (28) . The mixture was centrifuged at 1,000 g, the upper phase was transferred to another tube, the proteinaceous interface was washed twice with pure solvent upper phase, and the pooled washes and upper phase were then taken to dryness under N2. The dried residue was dissolved in 1 ml of assay buffer. An aliquot was counted for extraction recovery determination (range, 72-88%), and the remainder was subjected to taurocholate RIA. To assess the extent of fetal bile salt sulfation, extracts of fetal tissue were assayed by RIA, solvolyzed (29) , and then reassayed. Preliminary studies of solvolysis were performned with "4C-labeled standards of mono-, di-, and trisulfated taurocholate prepared by the method of Tserng and Klein (30) . These established that solvolysis permitted 92±+ 1.5% (mean±+-SEM) recovery of taurocholate from taurocholate sulfate. When the same standards were added to tissue samples and extracted as usual, the sulfates were quantitatively recovered (95-98% recoverv).
GLC was carried out with a Packard Gas Chromatograph (Packard Instrument Co., Inc.) equipped with flame ionization detectors. Bile acid methyl ester acetates (31) were chromatographed on 2-mm i.d. columns of 2% OV-210 on 80-100 mesh Gas-Chrom Q (Applied Science Lab, Inc., State College, Pa.) under the following conditions: oven temperature = 240°C, inlet and detector temperatures = 260°C, carrier gas flow rate = 40 ml/min. Each sample was analyzed first without, and then with added derivatized lithocholate internal standard. The bile acids in selected samples were also analyzed as the methyl ester trifluoroacetates on columns of 1% QF-1 (Supelco, Inc., Bellefonte, Pa.) at 215°C with similar results except that in these samples a-muricholate was not separated from cholate.
RESULTS
Specificity and sensitivity of the RIA. Based on the binding of the labeled taurocholate which had been added to the reaction mixture, 7 mol taurocholate/mol bovine serum albumin was bound in the protein-hapten Fetal Taurocholate 1043 complex. Rabbits developed measurable antibody titers as early as 1 mo after initiation of immunization. The highest titers (final antiserum dilution of Y4oo in the assay system) were obtained after -3 mo of immunization and were maintained with minimal variation for an additional 3-4 mo.
The specificity of the antibody-antigen interaction is summarized in Table I . The results, expressed as the percentage of cross-reaction based on the amount of test material required to displace 50% of bound [3H] taurocholate, show that only other taurine-conjugated bile salts gave significant displacement. Of these, taurocholate monosulfate, taurohyocholate, and taurochenodeoxycholate showed the greatest affinity for the antibody, at 42, 19, and 15% cross-reactivity, respectively.
A representative standard curve, generated by displacing bound [3H]taurocholate with pure, unlabeled taurocholate over a range of 0.5-100 pmol, is shown in Fig. 1 . The graph on the left (Fig. IA) is the sigmoid curve typical of RIA in which B/Bo (ratio of counts bound at a specific dose level to those bound at zero dose) is plotted against log dose. A logit plot of the same data (Fig. 1B) linearizes the sigmoid curve. The resulting straight line (r > 0.98) can be characterized by an equation, which can then be used to determine levels of taurocholate in unknown samples.
To validate the assay and the results, aliquots of fetal tissue bile salt extracts which had been analyzed by RIA were purified, hydrolyzed, and then subjected to GLC on 2% OV-210 as the methyl ester acetates.
Lithocholate was used as an internal standard after it was determined that it was not present in the fetal extracts and that other commonly used standards (hyodeoxycholate, nordeoxycholate, 518-cholanic acid-3a, 7a-diol-12-one) were either present in samples or not separated from other peaks. GLC patterns before and after solvolysis were not significantly different. The taurocholate content of each sample as determined by RIA was compared with the amount of cholic acid determined by GLC as shown in Fig. 2 From gestational day 19 onward, it was possible to assay liver, gut, and carcass separately, and the distribution of the fetal and neonatal taurocholate is shown in Fig. 4 determined by RIA. The abscissa is the age of the animal, in days gestation for fetuses (to the left of the break in the scale) and in days after birth for neonates (to the right of break). and 3-muricholate. At day 19 of gestation, all of the aforementioned bile salts were present, the relative proportions being 34, 26, 7, 16, and 17%, respectively. By 5 d after birth, however, the bile salt pool included only cholate (87%) and B1-muricholate (13%) (Fig. 5) . Hyocholate which, as a taurine conjugate, has the greatest cross-reaction with the taurocholate antibody in the RIA (other than taurocholate monosulfate), was not identified in any of the fetal samples.
Fetal response to maternal drug administration. Pregnant rats were treated with dexamethasone, 60 ,ug daily, from day 9 of gestation until sacrifice. Fetal taurocholate pool size is shown in Fig. 6 . At each age examined, the taurocholate pool size in animals from dexamethasone-treated mothers was significantlv larger than that of control fetuses or neonates. At 15 d, total body taurocholate of dexamethasone-treated rats was 180%, at 19 d, 140%, and at 1 d after birth, 120% of control values.
The distribution of taurocholate between liver and gut in the two groups was also substantially altered (Fig. 7) . At day 19 of gestation, although only 4% of the taurocholate pool was found in the gut of control fetuses, the gut of steroid-treated fetuses contained 41%. By 1 (Fig. :3) 7 Effect of maternally administered dexamethasone on the distribution of fetal and neonatal taurocholate. At each age (see Fig. 3 ), the mean percent of the total body taurocholate found in liver (stippled bars) and intestine (solid bars) is given for control and dexamethasone-treated animals.
DISCUSSION
In this study, the rates of accumulation and distribution of taurocholate in the rat fetus and newborn were examined. Where possible, fetal and neonatal bile salts were characterized by GLC, but, in addition, the limits of detection of taurocholate were extended by the development of a RIA relatively specific for this bile salt. Other taurine-conjugated bile salts crossreacted weakly with the assay antibody, and there was no cross-reactivity with glycine conjugates, free bile salts, steroids other than bile salts, or taurine itself. Cross-reactivity with monosulfotaurocholate was observed, but it was shown that sulfated bile salts are a minor fraction of the bile salt pool in the rat fetus and newborn. The Relocation of the primary site of the taurocholate pool from the liver to the gut is compatible with several interpretations. Direct entry of taurocholate from the plasma to the gut lumen might occur, but previous experience suggests that this process is minimal (13) , and uphill transport would have to be hypothesized to account for the observed concentrations. Increased hepatobiliary secretion or decreased intestinal reabsorption might account for the redistribution of Fetal Taurocholate taurocholate. Previous studies have established that the fetal gut is relatively permeable to taurocholate, and there is no evidence to suggest that this process changes significantly during the last third of gestation (37) . Inevitably, the early finding of taurocholate accumulations in the liver, and the progressive relocation of taurocholate into the intestine suggests that taurocholate secretion begins during the period between 19 and 21 d of gestation and continues to develop during late gestation and the first days after birth. These findings are consistent with the histologic changes of canalicular proliferation and maturation which are observed during the late fetal and early neonatal periods (38) (39) (40) .
Glucocorticoids produce an early increase in taurocholate pool size, and a redistribution of taurocholate to the intestine. Glucocorticoids induce the early maturation of a variety of hepatic enzymatic systems (41) , and stimulate the appearance of bile canaliculi in cell cultures of fetal rat hepatocytes (42, 43) . Bile salt synthesis and secretion are stimulated 20-fold in vitro by the addition of 1 uM cortisol to the medium of fetal hepatic organ cultures (36) . A retrospective clinical study suggested that the administration ofglucocorticoids to the mother during the last week of gestation increases bile salt pool size and synthesis rate in premature infants (18) . It is, thus, possible that the changes in fetal pool size and distribution observed in association with maternal glucocorticoid administration were the result of changes induced in fetal hepatic synthesis and secretion of taurocholate.
No alteration in taurocholate pool size or distribution was produced by the administration of phenobarbital to the mother. Phenobarbital is known to cross the placenta of the rat (44) . It has been shown previously, however, that in certain species of rats phenobarbital fails to induce the growth of hepatic endoplasmic reticulum in fetuses (44) . It appears, therefore, that in the fetal rat, phenobarbital fails to produce changes in bile acid metabolism comparable to those produced by glucocorticoid.
